The Roche group achieved sales of CHF 34.9 billion (€28.3 billion) in the first nine months of this year, up by 6% from the year-earlier period at constant exchange rates. The rise was fuelled by demand for the breast-cancer treatments Herceptin, Kadcyla and Perjeta.
